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INTRODUCTION 
Spontaneous bacterial peritonitis is the most frequent and important 
complication of cirrhosis with ascites. SBP is most frequently seen in severely 
decompensated cirrhotic patients. Since the infection occurs in the absence of a 
contiguous source of infection like intra – abdominal inflammatory focus eg: 
abscess, acute pancreatitis, cholecystitis, intestinal perforation, it is called 
Spontaneous. 
Based on culture, polymorphonuclear neutrophil counts of the ascitic 
fluid and the presence or absence of a surgical source of infection, ascitic fluid 
infection can be catagorized into five types. There are three types of 
spontaneous ascitic fluid infections. Spontaneous bacterial peritonitis is the 
prototype among them. 
SBP accounts for 25% of all infections and 9% of hospitalised patients 
with cirrhosis(1). When a cirrhotic patient, particularly with encephalopathy and 
or jaundice detoriates, SBP should be suspected. An ascitic fluid protein of less 
than 1 g/dl predisposes to SBP(2). Patients with a previous episode of SBP are 
at a particular risk. Patients with variceal bleeding are also at high risk of 
developing SBP. 
Systemic vascular changes in response to the infection can lead to renal 
complications in patients with SBP(3). Prognosis is worse in patients with SBP. 
They have a high morbidity and mortality. 10% to 20% of patients die during 
that hospital admission. The median survival of a patient who develops SBP is 
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approximately 9 months(4). SBP recurrence is also not uncommon. The 1 year 
probability of SBP recurrence is 69%. 
In patients with uncomplicated SBP (i.e. no renal dysfunction, no 
encephalopathy), SBP resolution and immediate survival is 100 %, whether the 
patients receive oral or intravenous antibiotics(5). Recurrent SBP in a cirrhotic 
patient with ascites is an indication for hepatic transplantation, because of 
reduced survival. 
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REVIEW OF LITERATURE 
The prototype form of spontaneous ascitic fluid infection is the 
spontaneous bacterial peritonitis(6). The term spontaneous bacterial peritonitis 
was coined by Corriea and Conn in 1975. Their aim was to differentiate 
spontaneous bacterial  peritonitis from surgical peritonitis(7). 
Classification for ascitic fluid infections was proposed in 1998(8). This 
classification is based on the ascitic fluid culture, the counts of the 
polymorphonuclear neutrophils and also depending on the absence or presence 
of a surgically treatable source of infection     
 Classification of Ascitic fluid infection: 
1. Spontaneous ascitic fluid infection 
Spontaneous bacterial peritonitis 
Culture negative neutrocytic ascites 
Monomicrobial nonneutrocytic ascites 
2. Secondary bacterial peritonitis  
Gut perforation 
Non perforation 
3. Polymicrobial bacterascites 
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SPONTANEOUS BACTERIAL PERITONITIS:  
The diagnosis of this form is made in the presence of an elevated 
polymorphonuclear neutrophil count  ≥ 250 cells/cumm and a ascitic fluid 
culture positivity and without any evidence of  surgically treatable external or 
intra - abdominal source of infection(9). Most of the cases show growth of a 
single organism(10) 
Culture negative nonneutrocytic ascites:  
The term CNNA was proposed in 1984(11). It is a variant of SBP which 
is associated with a lower mortality as compared to SBP(12). A PMN  count  of  
> 250 cells /cumm and a negative ascitic fluid culture in the absence of even a 
single dose of antibiotic  suggest CNNA(11). Such and Runyon(8) have proposed 
that other causes of neutrocytic ascites (tuberculous peritonitis, peritoneal 
carcinomatosis, pancreatitis) must be ruled out before a diagnosis of CNNA is 
made. These patients must be treated similar to SBP patients as their clinical  
presentation, therapeutic and prognostic characteristics resemble that of SBP.  
Monomicrobial nonneutrocytic ascites:  
This variant is diagnosed when the PMN counts are < 250 cells/cumm 
and the ascitic fluid shows culture positivity for a single organism with no 
evidence of surgically treatable cause of intraabdominal source of infection(13).  
SECONDARY BACTERIAL PERITONITIS: 
This is diagnosed when the ascitic fluid PMN counts are ≥ 250 
cells/cumm, culture showing polymicrobial organisms and an identifiable 
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surgically treatable intraabdominal  primary source of infection.The infection 
can occur with or without  intestinal perforation(14).  
POLYMICROBIAL BACTERASCITES: 
This variant is diagnosed when the PMN counts are < 250 cells/cumm 
and the ascitic fluid shows cultures of multiple organisms. Earlier studies(8) 
have shown that this is a rare event seen in about 1 in 1000 paracentesis, 
occurring due to inadvertent perforation of the intestines while performing 
paracentesis. They have identified various risk factors for this iatrogenic form 
of infection which include multiple surgical scars, ileus and the inexperience of 
the operator in performing the procedure. 
PREVALANCE OF SPONTANEOUS BACTERIAL PERITONITIS:  
In the 1980’s, approximately 10% of the ascitic fluid were found to be 
infected at the time of admission to hospital. A low frequency might be due to 
the infrequency of paracentesis and the low diagnostic efficacy of bacterial 
cultures. In the recent days SBP is identified earlier itself due to better 
techniques of ascitic fluid analysis and culture and also due to routine 
paracentesis performed at the time of admission and hence the complication 
rate is reduced to < 1%(15). 
In the recent days, paracentesis is performed as a routine in patients with 
ascites getting admitted to the hospital for various reasons.In patients with a 
positive culture fluid, Monomicrobial Bacterascites constitute about 1/3 rd and 
the remaining  2/3 rd constitue SBP(13).  
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Prevalence of CNNA is largely dependent on culture techniques(15). The 
frequency of  Polymicrobial bacterascites is low, seen in about 1 per 1000 
patients(16). About  0 - 2% of  patients with ascites at the time of admission to 
the hospital are found to have Secondary bacterial peritonitis(17). About 5% of 
the patients initially diagnosed as to have SBP are later proved to be secondary 
bacterial peritonitis. 
PATHOGENESIS: 
Harold Conn in 1975 used the term spontaneous in describing bacterial 
peritonitis in the ascites patient to indicate that the infection appeared from 
nowhere(7). Current evidence suggests that the spontaneous ascitic fluid 
infections are due to translocation of the bacteria from the intestine to the 
mesenteric lymph nodes which results in spontaneous bacteremia and 
subsequent colonization of ascitic fluid(18). 
INTESTINAL BACTERIAL TRANSLOCATION: 
Study conducted in 1998 has shown that about 30 to 48% of patients 
with cirrhosis have colonization of the upper bowel with colonic bacteria and 
the rate of colonization increases in patients with more advanced liver 
disease(8). 
Bauer et al and Guarner et al have demonstrated the overgrowth of a 
specific organism, particularly potentially pathogenic bacteria such as 
enterobacteriaceae. It has been found that intestinal bacterial overgrowth is a 
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prerequisite for bacterial translocation in experimental animals with 
cirrhosis(19,20). 
In the study by Such et al, it was proposed that intestinal bacterial 
overgrowth  in patients with cirrhosis may be due to a combination of alteration 
in the local IgA immune response and delay in the intestinal transit(8).  
Also in cirrhotics, there are changes in the Paneth cell Defensins, 
presence of portal hypertensive enteropathy and a decrease in pancreato – 
biliary secretions(21). 
Wiest and Tsao(22) in their study have shown that three main factors are 
found to be linked in the pathological bacterial translocation.  
These include: 
1) Alterations in the gut microbiota  
2) Increase in the intestinal permeability 
3) Impairment in the host defence 
GUT MICROBIOTA: 
Spontaneous infections of the ascitic fluid are mainly gut derived 
bacteria(23). Gram negative aerobic rods such as E coli and Klebsiella 
pneumoniae are the causative in majority of cases of SBP. The enteric nature of 
these organisms indicate the gut as their source(6). Occasionally Pneumococcus 
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is also isolated that does not reside in the gut. These organisms cause SBP and 
MNB. Anaerobes account for only 1% of SBP(24). 
SBP, MNB, CNNA are probably as a result of the colonization of 
susceptible ascitic fluid  as a result of spontaneous bacteremia or the weeping 
of  bacteria laden lymph from the liver capsule as it forms ascitic fluid. 
Although direct transmural migration of bacteria from the gut into ascitic fluid 
has been postulated, the loss of gut mucosal integrity has also been 
documented. Bacteria translocate from the gut lumen across the submucosal 
lymphatics and are detected in mesenteric lymph nodes(25). From the mesenteric 
lymph nodes the bacteria spreads to spleen, liver or blood stream. 
INTESTINAL  PERMEABILITY : 
Along with a reduction in intestinal motility, structural and functional 
alterations in the intestinal mucosa have been demonstrated in patients with 
cirrhosis. These changes lead to an increase in the permeability of intestine to 
bacterial products. 
The intestinal permeability is also altered by the changes occurring in 
the   mitochondrial functioning of the enterocytes  and an increased oxidative 
stress of the intestinal mucosa(26, 27). 
HOST DEFENCE FACTORS: 
Alterations occur in the local and systemic immune defences in patients 
with cirrhosis which can lead to spontaneous infection of ascitic fluid. In 
healthy individuals, bacteria that colonize the lymph nodes are killed by local 
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immune defences. However in the setting of cirrhosis, several forms of immune 
deficiency is seen which favour the spread of bacteria to the blood stream. 
Several abnormalities occur in both the humoral and cellular bactericidal 
systems. A poor function and phagocytic activity of neutrophils , decreased 
serum complement levels, a decreased macrophage function and 
reticuloendothelial system dysfunction(28) is common in cirrhosis. These defects 
in host defences would lead to frequent and prolonged bacteremia. 
LOCAL ASCITIC – PERITONEAL HOST DEFENCE IN 
PERITONITIS: 
Ascites per se may be considered as a risk factor for the development of 
peritonitis. In healthy individuals, an efficient peritoneal defence mechanism 
clears off the entering organisms very efficiently(29). But due to deficiencies in 
local defence mechanisms against bacteria in cirrhosis, the clearance of 
peritoneal bacteria is limited. 
The absolute number of PMN influx per cumm of ascitic fluid and the 
overall killing capacity determines the bacterial clearance.  The resident 
macrophages attract PMN by releasing chemotactic factors and also by 
activating the complement factors. One of the most potent chemokine 
identified is the Monocyte Chemotactic protein 1. In patients with cirrhosis due 
to alcohol, a functional polymorphism in this chemotactic protein has been 
demonstrated which has been proposed as a risk factor for the development of 
SBP in these patients(30). A chemotactic gradient is essential to achieve 
appropriate neutrophil recruitment into the peritoneal cavity. Unfortunately 
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little is known about the influx, efflux, and kinetics of neutrophils in ascitic 
fluid in cirrhosis. 
Opsonic and bactericidal activity is reduced in patients with cirrhosis. A 
low opsonic activity is associated with a low C3 level and a low total protein 
content(31). A C3 level of < 13 mg /dl is associated with ascitic fluid infection. 
The incidence rates of SBP have been consistently < 1% when the ascitic fluid 
protein levels are >1.5g/dl. With protein levels of < 1.5 mg/dl of ascitic fluid, 
the risk of SBP increases parelling the decrease in protein content and the 
incidence rate increases to 27 – 44%  at levels < 1g /dl(32). 
The levels of adipokines in ascites which modulate the inflammatory 
response are found elevated in the presence of SBP. These include adiponectin, 
visfatin and resistin(33). 
SYSTEMIC RISK FACTORS & LIVER DYSFUNCTION: 
A decreased reticuloendothelial system activity in patients with cirrhosis 
is associated with a higher rate of incidence of SBP. A study(34) in 1984 has 
demonstrated a relationship between bacteraemia, SBP and impaired 
reticuloendothelial activity and this impairment in function is due to either 
functional and/or anatomical shunts. 
Various markers of advanced liver dysfunction have been identified as 
important risk factors for the development of SBP in a study done in 2007(35).  
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These  include : 
1) bilirubin level greater than 3.2 mg/dl   
2) platelet count of less than 98,000 /cumm 
3) each point of MELD increases the risk of SBP by about 11%  
GENETIC INFLUENCE: 
Studies have demonstrated the various genetic variants influencing host 
defence mechanisms(36,37). Persons with genetic variants such as CARD 
15/NOD 2(36) and TLR 2(37) polymorphisms have been found associated with an 
increased probability of acquiring SBP. 
INFLUENCE OF MEDICATIONS: 
The chances of SBP in a cirrhotic patient with ascites can be influenced 
by the use of adjunct medications like proton pump inhibitors. Use of PPI may 
lead to pathological bacterial translocation by facilitating SIBO. This has been 
proved by a retrospective study(38). Cirrhotic patients are found to have frequent 
inadequate overuse of PPIs which increases the risk of acquiring SBP. 
Whereas, Non selective Beta Blockers have been shown to prevent 
SBP(39). Various experimental settings have reported that an improvement in 
the chemotaxis, killing capacity and release of proinflammatory cytokines is 
found in patients who are on beta blockers(40). 
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CNNA:  
CNNA episodes are due to insensitive culture methods. Here the number 
of bacteria are insufficient to reach the threshold of detectability(15). Studies 
have shown that a small percentage of specimens of neutrocytic ascitic fluid 
grow no organisms even when optimal culture methods are used for culture of 
bacteria(9). 
In the setting of sensitive culture techniques, CNNA probably represents 
spontaneously resolving SBP in which the tap is performed after all bacteria 
have been killed by the host defences but before the PMN count has 
normalised. Canawati et al in their study have shown that culture by 
inoculation of ascitic fluid into agar plates and broth probably may require at 
least 100 organisms /ml(15). Also CNNA may probably be due to antibiotic 
treatment, even a single dose and due to inadequate volume of fluid inoculated. 
MNB:    
Mononuclear non – neutrocytic bacterascites (positive culture, PMN 
<250 cells/cumm) was labelled in the older literature as Asymptomatic 
Bacterascites. Human and animal studies have shown that MNB is common. 
They usually resolve without antibiotic treatment(41). The invading bacteria are 
efficiently eradicated by the hosts defence mechanisms on most of the 
occasions. The fluid shows no increase in ascitic PMN’s and it becomes sterile. 
But when the organism is virulent and the defences are weak, they can progress 
to SBP(13). An ascitic fluid infection in the early stage may be probably 
indicated by MNB. Bacterascites is much more common than SBP. 
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SECONDARY BACTERIAL PERITONITIS: 
Pathogenesis of secondary bacterial peritonitis occurs in the setting of 
frank intestinal perforation or without frank perforation. In frank intestinal 
perforation, the ascitic fluid is flooded by billions of bacteria. In the absence of 
frank perforation, bacteria may enter the ascitic fluid by crossing the 
inflammed tissue planes as in the case with perinephric abscess or empyema of 
the gall bladder(16). 
POLYMICROBIAL BACTERASCITES: 
Polymicrobial bacterascites occurs in the setting of inadvertent bowel 
puncture with paracentesis needle while doing the procedure.  Bowel contents 
with bacteria are released into the ascitic fluid and leads to infection. But with 
high protein ascites, it usually resolves without antibiotic therapy(16). 
BACTERIAL FLORA:  
Various studies  have demonstrated Gram negative bacteria as the most 
frequent group of organisms isolated. They contribute to about 60% of episodes 
of SBP(15). Eschcerichia Coli, followed by Klebsiella pneumonia and 
streptococci (mostly pneumococci) cause most episodes of SBP & MNB. Gram 
positive cocci account for about 25% of the episodes and they include 
Pneumococcus, Strep viridians, Staph aureus and the most frequently isolated 
species are the streptococci. Although anaerobes dominate the colonic flora 
they are isolated rarely from the ascitic fluid. This probably may be explained 
by the fact that the intestinal wall and surrounding tissues contain a high 
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content of oxygen which might inhibit the growth of anaerobes.And also the 
anaerobes have a relative inability to translocate across the intestinal mucosa 
and this may lead to a rarity of demonstration in ascitic fluid(8). Older reports 
have shown that 6% of cases of SBP were due to anaerobes, but recent reports 
have shown anaerobes in approximately 1% of cases of SBP & MNB(15, 24). The 
detection of anaerobes in ascitic fluid should raise the suspicion of a case of 
secondary bacterial peritonitis left unrecognised. An increasing incidence of 
SBP due to gram positive organisms has been demonstrated by studies(42). 
PREDISPOSING FACTORS FOR SBP INCLUDE(8):  
Child Pugh Class C 
Ascitic fluid protein < 1g /dl 
Ascitic fluid C3 levels < 13 mg / dl 
Gastrointestinal bleeding 
Urinary tract infection 
Iatrogenic factors : urinary bladder and intravascular catheterisation 
Previous episodes of SBP 
 In patients with cirrhosis, cirrhosis is itself a form of acquired 
immunodeficiency status. A pre-existing phagocytic dysfunction and an ascitic 
fluid with a low protein concentration in a cirrhotic can predispose them to 
bacterial infection. 70 % of the patients who develop SBP are in class C and the 
remainder being class B. 
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Andreu et al have demonstrated a serum total bilirubin  level  of  >2.5 
mg /dl is an independent risk factor for development of SBP(43). 
A direct correlation between total protein level, complement 
components and opsonic activity explains why an ascitic fluid total protein 
level of <1 g/dl is a risk factor for the development of ascitic fluid infection 
In patients with gastrointestinal hemorrhage, the probability of 
nosocomial infection following hospitalization is approximately 50% and 20% 
have ascitic fluid infection at the time of admission to the hospital(44). The risk 
peaks about 48 hrs after the onset of the bleed. Study done in 1996(45) has 
reported that the gastrointestinal hemorrhage leads to a status of shock. An 
increased bacterial translocation occurs from the intestines to extraintestinal 
sites and there is a decreased effectiveness of the reticuloendothelial system in 
the status of shock.  
Such and Runyon have reported in their study that ascitic fluid 
infections in 4% of patients have occurred due to intravascular catheters. 
Those patients who survive an episode of SBP are at a higher rate of 
recurrence: 43% at 6 months, 69% at 1 yr, and 74% at 2 yrs(8). 
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PATHOGENESIS OF SPONTANEOUS ASCITIC FLUID INFECTION 
 
CLINICAL PRESENTATION: 
About 87% of patients are symptomatic at the time of diagnosis (13).The 
symptoms and signs are often subtle or usually misinterpreted(13). Minor 
changes in the mental status may be the sole evidence of infection. These 
mental changes would only be detected by family members or family 
physician. 
The most frequently observed symptoms according to Such and 
Runyon(8) are   
1) fever – 69 % 
2) abdominal pain - 59% 
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3) hepatic encephalopathy – 54% 
4) abdominal tenderness  - 49% 
5) diarrhea – 32% 
6) ileus – 30% 
7)  shock – 21% 
8) hypothermia – 17% 
9) Asymptomatic – 10%  
DIAGNOSIS:  
Many patients with SBP are asymptomatic(46). So whenever a patient 
with ascites gets admitted to the hospital regardless of the presence or absence 
of  clinical symptoms suggestive of SBP, a diagnostic paracentesis should be 
performed. Clinical detoriation in a patient with ascites in the form of fever, 
abdominal pain or increasing abdominal distension is more suggestive of 
ascitic fluid infection.  
Ascitic fluid analysis for TC, PMN count, biochemistry and a 
simultaneous bedside inoculation of the ascitic fluid into the blood culture 
bottles must be done. A prompt diagnosis should be made and treatment should 
not be delayed until the culture results become available. Guidelines suggest 
that diagnosis should be based on a fixed cut-off of PMN count in the ascitic 
fluid(6). A cut-off value with the greatest sensitivity is 250 PMN cells /cumm 
and with greatest specificity is 500 PMN cells /cumm(47). However, the most 
sensitive cut-off of 250 is used for diagnosis not to miss cases. SBP caused by 
gram positive cocci has been reported to have a PMN count of < 250 /cumm. 
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PMN cells should be corrected in case of hemorrhagic ascites i.e. red blood cell 
count >10,000 /cumm. Subtraction of one PMN per 250 RBC’s should be made 
to adjust for the presence of blood in ascites.  
USE OF AUTOMATED CELL COUNTER: 
PMN in the ascitic fluid can be determined either by manual counting 
chamber under a light microscope or by automated cell counter. The specific 
method to be used is not stated in the current guidelines .The use of automated 
cell counters has been recently validated in patients with cirrhotic ascites 
according to Riggio et al(48 ,49). They reveal sufficient sensitivity in the 
detection of SBP and hence are recommended. 
USE OF REAGENT TEST STRIPS: 
Use of reagent test strips to assess leucocyte esterase activity of 
activated PMNs needs to be confirmed in large multicentre trials and the test is 
not interpretable in bloody, chylous or bloody ascites. Mendeler et al(50) in their 
study recommend the usage of a reagent strip test that has been developed 
recently which has been calibrated to a cut – off of 250 PMN/cumm in ascitic 
fluid. This has been shown to have a sensitivity of 100% and a negative 
predictive value of 100%.However large multicentre trials are needed to 
validate its use. 
CULTURE METHODS: 
Runyon et al proposed culture of the ascitic fluid to be done by bedside 
inoculation of the ascitic fluid into blood culture bottles(15). About 10 ml of 
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inoculum into the bottle has shown to optimise the results in standard 100 ml 
bottle. In the older method  agar plates inoculation and some broth with a few 
drops of fluid were used for culture of  the ascitic fluid. They were very 
insensitive methods and only 50 % of the neutrocytic samples demonstrated 
bacterial growth. Bedside inoculation of the ascitic fluid into blood culture 
bottles has shown to increase the sensitivity to nearly 80%(51, 52). Culture is also 
essential for assessment of the susceptibility of the organism to antibiotic. False 
negative reports can occur due to error in the handling processes and a delay in 
the transport of the ascitic fluid(53).    
BACTERIAL DNA DETECTION:  
Detection of bacterial DNA using gene probes is now commercially 
available.  Frances et al have demonstrated bacterial DNA in ascitic fluid in 
about 40% of patients with cirrhosis, which is derived mainly from gram - 
negative bacteria(54). The incidence  of  SBP in these patients is not predicted 
by the detection of bacterial DNA either in ascites or in serum. The main 
advantage of this system of detection of  bacterial DNA would be to identify 
the causative bacteria immediately so that a targeted antibiotic treatment can be 
started early and prevent mortality.   
OTHER MARKERS OF INFLAMMATION IN ASCITIC FLUID: 
The utility of other tests in ascitic fluid such as ascitic fluid pH, LDH, 
Cholesterol, Fibronectin, α 1 – AT, Glysosaminoglycans has not proven any 
benefit and these tests are not recommended(8) 
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RULING SECONDARY BACTERIAL PERITONITIS:  
Since the mortality associated with secondary bacterial peritonitis is 
high, they should be diagnosed early and differentiated from SBP(55). Timely 
surgery is essential in them to prevent death during hospitalization. The clinical 
symptoms and signs closely resemble that of SBP and also a classic surgical 
abdomen does not develop even with perforation of the colon. 
Intestinal perforation should be suspected in the setting of a neutrocytic 
ascites with at least two of the following three criteria(56):  
1) ascitic fluid total protein >1 g /dl 
2) glucose < 50 mg / dl 
3) LDH > 225 mU /ml  
This is proposed by Runyon et al and has a sensitivity of < 68%. Ascitic 
fluid culture in a perforated viscus is nearly always polymicrobial. When there 
is no response to antibiotic therapy in a suspected case of  SBP, then secondary 
bacterial peritonitis should be  considered and ruled out. 
TREAMENT OF SBP: 
Treatment should be started immediately after diagnosis of SBP and it is 
empirical since culture results are not available at that time point. The 
antibiotics used should have a high killing capacity against the bacteria and 
also should achieve high concentrations in the ascitic fluid .Most data support 
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the use of Cefotaxime 2 g intravenously every 8 hours as the empirical 
antibiotic.  
Antibiotics without any data on their penetrating capacity of the ascitic 
fluid should be avoided. Empirical treatment is indicated in patients with an 
ascitic fluid PMN count of ≥ 250 cells/cumm and with clinical features 
suspicious of ascitic fluid infection. The difference in the type of antibiotic 
treatment to be used in nosocomial and community – acquired SBP is not 
addressed to by any guidelines. High rates of bacterial multiresistance and 
mortality are seen in patients with nosocomial acquired SBP(57). Health care 
associated infections are also more frequent in cirrhotic patients(58). 
COMMUNITY ACQUIRED SBP: 
In patients with no prior hospitalization and antibiotic treatment, the 
causative organisms for SBP are the enterobacteriaceae family, which are 
easily treatable. Cefotaxime or other third generation cephalosporins are the 
drug of choice. 
Cefotaxime given in the dose of 2g IV every 8 hrs has shown to result in 
excellent ascitic fluid levels (20 fold killing power after a single dose). It 
reaches high ascitic fluid concentrations during therapy(5,59,60). Rimola et al 
have achieved a resolution of infection in 77 – 98% of patients(50). A 
randomised control study by Runyon and Hutchinson have shown that a 
duration of treatment for 5 days is as effective as10 day treatment(59). The 
dosage need not be altered for hepatic or renal failure. Ceftriaxone is highly 
protein bound & penetrates low protein ascites poorly. Ceftriaxone has a role in 
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the prevention of bacterial infections in patients with cirrhosis and 
gastrointestinal hemorrhage. 
DOSING INTERVALS:  
Studies(61) have recommended the dosing interval of 8 – 12 hrs in ideal 
conditions, 8 hrs for a serum creatinine of < 3 mg /dl and 12 hrs for more 
severe renal failure. Dosing more frequently than every 8 hrs is not necessary 
because high ascitic fluid concentration of (>20 fold the MIC of >90 % of the 
flora) of the drug is attained after one dose and is sustained during every 8 hrs 
dosing(61). Neither a loading dose nor an intraperitoneal dose appears to be 
necessary. When susceptibility testing results are available a more narrower 
spectrum antibiotic can be changed. 
OTHER IV ANTIBIOTICS:  
IV Amoxicillin / Clavulanic acid in the dose of 1g every 8 hrs has 
shown comparable efficacy as IV Cefotaxime in earlier trials. 
Ciprofloxacin given either for 7 days IV or for 2 days IV followed by 
orally for 5 days results in SBP resolution rate similar to Cefotaxime.(62)  
ORAL ANTIBIOTICS: 
In patients without any complicating factors that may precipitate the 
therapeutic efficacy, oral treatment with Quinolones are found to be as 
effective as parenteral Cefotaxime in the treatment of SBP(5). Oral Ofloxacin is 
administered in the dose of 400 mg bd for an average of 8 days in patients who 
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do not have vomiting, shock, bleeding or renal failure. Empirical use of a 
fluoroquinolone to prevent  spontaneous bacterial peritonitis should be avoided 
as there is a high risk of development of resistance to these drugs in these 
patients(63). But however patients with spontaneous bacterial peritonitis in 
whom fluoroquinolones were given as a prophylactic antibiotic are still found 
to be susceptible to Cefotaxime.  
NOSOCOMIAL SBP:  
The use of third generation Cephalosporins, Amoxicillin /Clavulanic 
acid or Quinolones  in patients with Nosocomial SBP has been found to be 
associated with a low resolution rates(64). The reasons for this might be due to 
increasing resistance to these antibiotics, the increasing incidence of extended 
spectrum β – lactamase (ESBL) producing bacteria as well as multiresistant 
gram – positive bacteria such as  Enterococcus faecium or methicillin resistant 
Staphylococcus aureus (MRSA). 24-27% of cases of SBP are found to be due 
to MRSA(65). ESBL’s  leads  to  resistance  to  various  antibiotics  including  
third – generation Cephalosporins and Monobactams, and also carry genes 
encoding resistance to antibiotics like Quinolones, Tetracyclines and 
antifolates. The patients with nosocomially acquired multiresistant organisms 
are associated with increased morbidity, mortality and health care – associated 
costs(57). First – line empirical antibiotic treatment is often results in failure to 
response in these patients(57). The treatment in these patients should be 
stratified based on the host factors as well as on the validated knowledge of the 
resistance profile of the bacteria in the setting in which the patient is diagnosed 
and treated. Previous hospitalization, within the previous three months, ICU 
 
24
treatment, and prior prophylactic or therapeutic antibiotic treatment can 
contribute to bacterial multiresistance to antibiotics(66).  It is therefore suggested 
that those patients  with risk factors of likelihood of developing multidrug 
resistance and patients with SBP acquired nosocomially, a more effective first 
–line empirical antibiotic treatment with a broader spectrum drug like 
Carbapenems should be employed. Also the rate of success of use of antibiotics 
like Cefotaxime and Amoxicillin – Clavulanic acid in patients with 
nosocomially acquired SBP is as low as 44% and so extended spectrum 
antibiotics are preferred These drugs can be changed later if the 
microbiological results reveal non – resistant antibiotic susceptible 
bacteria.Broad spectrum antibiotics are the choice of initial empirical therapy 
in patients with hospital acquired SBP, especially in those who had been on 
Beta – Lactams during admission, had been recently hospitalized or on 
Quinolone prophylaxis. 
TREATMENT OF MONOMICROBIAL BACTERASCITES: 
It is controversial whether immediate antibiotic treatment is required in 
a patient with Monomicrobial Bacterascites without an increase in the PMN 
count. They are special cases with regards to empirical treatment as many 
episodes resolve without treatment. But with possibility of many cirrhotic 
patients being asymptomatic even in the presence of infection, it is mandatory 
to start on antibiotic treatment. Some patients may progress to SBP, and 
therefore all patients should receive treatment.Empirical treatment can be 
discontinued after 2 -3 days later if the culture remains negative. 
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TREATMENT OF CNNA :  
Empirical treatment should be started as the treating physician is not 
aware of that the culture would show no growth. A repeat paracentesis should 
be done to assess the response of polymorphonuclear count to the given 
treatment .The response to treatment can be confirmed by a decrease in the 
polymorphonuclear counts. A reduction in the PMN count below the baseline 
and frequently more than 80% reduction confirms the response to treatment 
and the treatment has to be continued for a few more days(67).    
ADJUVANT TREATMENT: 
SBP is associated with a worsening of renal function and Llovet et al 
have demonstrated renal impairment in about 33% of the patients with SBP(68). 
This is due to the increased production of intraperitoneal nitric oxide in 
spontaneous bacterial peritonitis which in turn leads to an increase in the 
systemic vasodilatation and leads on to renal failure.  
IV Albumin with Cefotaxime has prevented worsening with a 
concomitant improvement in the in - hospital and 3 - month mortality(69). It is 
given in the dose of 1.5 g / kg on day 1 and 1 g / kg on day 3. Trials have 
shown that adjuvant administration of high – dose albumin along  with 
antibiotics acts by decreasing the vasodilatation and increasing intravascular 
volume. Because of survival advantage, the use of IV albumin as a adjunct 
treatment has been recommended. The patients who benefit most from the 
administration of albumin are those with renal dysfunction at baseline, sr 
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creatinine > 1mg/dl and /or blood urea nitrogen >30 mg/dl and sr bilirubin > 
4mg/dl.(70) 
DURATION OF TREATMENT: 
Recommended duration of treatment is for 5 days. Extension of 
treatment to 10 days has not been found to be superior to 5 days of treatment as 
shown in a comparative study(71). Antibiotic treatment can be safely 
discontinued after the PMN count has decreased to < 250 cells / cumm. So a 
repeat paracentesis should be done after 48 hrs to determine the levels of PMN 
count in the ascitic fluid(14). Current guidelines suggest that an absence of 
decrease in the PMN counts by at least 25% compared with the pretreatment 
levels after 2 days of antibiotic treatment, then the antibiotic treatment has to be 
changed(28). 
PREVENTION OF SBP: 
ANTIBIOTIC PROPHYLAXIS: 
Emergence of resistant bacteria is a problem encountered in long term 
prophylaxis(1). So prophylactic antibiotics are indicated only in patients with 
the highest risk of developing SBP. Prophylaxis is considered in patients with 
ascitic fluid protein concentration  <1.5 mg /dl,variceal hemorrhage, child –
pugh score of  ≥ 9 , total bilirubin ≥ 3 mg/dl, sr creatinine of  ≥ 1.2 mg /dl, sr 
sodium of < 130 mEq/l, or blood urea nitrogen of  ≥ 25 mg/dl and those with a 
previous episode of SBP, Cirrhosis with gastrointestinal hemorrhage(72 ,73). In 
the setting of upper GI hemorrhage, Norfloxacin 400 mg twice daily for 7 days 
is recommended to prevent SBP (74). Recently IV Ceftriaxone 1g daily for 7 
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days is found to be more effective than Norfloxacin in the setting of GI 
hemorrhage, and in patients  with  advanced  cirrhosis  ie:  with  at  least  two  
of the following : ascites, severe malnutrition, encephalopathy or bilirubin >3  
mg /dl(75). It can also be administered in patients who are vomiting blood(75). 
Norfloxacin 400 mg daily is effective in reducing the risk of  SBP in patients 
with low ascitic fluid protein and with prior episodes of SBP(72). In patients 
with previous episode of SBP, Norfloxacin 400 mg orally once daily has to be 
given until death or liver transplantation. Some guidelines recommend the use 
of oral Ciprofloxacin 750 mg once weekly or Trimethoprim / Sulfamethoxazole 
in the dose of one double strength tablet daily as an alternative(76). In patients 
with ascitic fluid total protein > 1 g /dl and without prior history of SBP, 
prophylaxis is not necessary as the 1 – year probability of SBP is nil(32). 
Prophylactic administration of antibiotics has shown to reduce the rate of 
recurrence significantly. There is 66% reduction in recurrence in patients with 
prior SBP administered with Norfloxacin.In a cirrhotic patient with 
gastrointestinal hemorrhage, prophylaxis with Norfloxacin has shown to reduce 
the rate of infection by 73% and Ceftriaxone by 67%. In a patient with cirrhosis 
and ascitic fluid total protein < 1.5 g/dl, prophylaxis with  Ciprofloxacin 500 
mg orally daily  for 1 year has shown to reduce the rate of infection by 31% 
and also improves the survival rate by 30%. Norfloxacin prohylaxis in the 
setting of predisposing conditions  has shown to reduce SBP by 89%, 32% 
reduction in the development of  hepatorenal syndrome, 52% increase in the 3- 
month survival  and 25% increase in the 1-year survival.(74,75)    
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ALTERNATIVE PROPHYLACTIC MEASURES: 
1) Since the continuous use of single antibiotic may lead on to 
resistance formation, antibiotic cycling should be tried to 
overcome this. 
2) Rifaximin can be tried as it belongs to a class of antibiotics 
different from the antibiotics tested so far, with broad 
antimicrobial activity against gram positive bacteria, less 
bacterial resistance, acting predominantly in the small 
intestine(77). 
3) Probiotics have been found efficacious in correcting the bacterial 
overgrowth, improving the neutrophil function, stabilising the 
mucosal barrier function, and decreasing bacterial translocation 
in experimental animal(79). The development of bacterial 
resistance may be limited by using probiotics and trials are 
ongoing in this regard. 
4) The bacterial infections which occur postoperatively after liver 
transplantation has been decreased with the addition of fibre to 
lactobacilli.(79) 
PROGNOSIS & OUTCOME: 
A prospective study documented a recurrence rate of 69 % at 1 year(4). 
An ascitic fluid protein level of < 1 g/dl was the best predictor of recurrence. 
About 48 - 95% of the patients with spontaneous fluid infections died in the 
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past in spite of treatment during the hospitalization(80). Recent series have 
reported a <10% hospital mortality(70) and the mortality can be reduced to < 5% 
if timely and appropriate antibiotics are started and infection is identified 
earlier(70). 
Patients who have had already one episode of SBP are at a high risk of 
recurrence, with rates of 43% at 6 months, 69% at 1 year, 74% at 2 years(4). 
The median survival of a patient who develops spontaneous bacterial peritonitis 
is 9 months.(4) 
Renal impairment is a frequent complication of spontaneous bacterial 
peritonitis. It is reported in about 33% of episodes of SBP(68). Administration of 
intravenous albumin has been found to improve survival and outcome in these 
patients. The main predictors of death in a patient with spontaneous bacterial 
peritonitis would be determined by the  nosocomial acquisition of infection and 
associated renal dysfunction. An uncomplicated community acquired 
spontaneous bacterial peritonitis i.e. with no renal impairment, no hepatic 
encephalopathy, the resolution of SBP and immediate survival is about 100% 
whether they receive oral or intravenous antibiotics.(5) 
An episode of SBP is an indication for liver transplantation as it is a 
marker for ESLD(80). To maximise survival, paracentesis should be performed 
in all patients with ascites at the time of hospitalization, so that infection can be 
detected and treated promptly.  
The probabilities of 1 year and 2 year survival rates are in the range of 
30% and 20 % respectively(8). 
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AIM OF THE STUDY 
1) To determine the Incidence, Microbial spectrum, Clinical and 
Biochemical spectrum of SBP and its variants in patients with Cirrhosis 
and Ascites. 
 
2) To study the natural history and outcome of patients with SBP 
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MATERIALS AND METHODS 
This is a prospective, observational study. The study was conducted in 
the Department of Digestive Diseases and Health, Anna Nagar Peripheral 
Hospital from August 2012 to January 2013. 180 consecutive chronic liver 
disease patients with ascites of varied etiology, admitted in the ward were taken 
for the study. 80 patients were eliminated from the study as they were 
associated with other causes of ascites, associated with malignancy or other 
comorbid illness.100 patients who fitted into the inclusion criteria were 
analyzed for the presence of SBP. In all patients cirrhosis was confirmed by a 
combination of Biochemical, Haematological parameters & Ultrasound 
abdomen.  
Ethical committee approval was obtained before proceeding with the 
study. Willingness of the patients included in the study to undergo 
investigations was obtained, along with written informed consent. 
INCLUSION CRITERIA: 
1) Cirrhotic patients between  20 and 70 years. 
2) Both sexes 
3) Patients with cirrhosis and ascites 
4) Patients presenting with fever, chills, abdominal pain, recent 
increase in the abdominal distension, confusion or coma, rebound 
tenderness, or signs of hepatic encephalopathy  
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5) Patients with ascitic fluid  polymorphonuclear  neutrophil count  
≥  250 cells /cumm 
EXCLUSION CRITERIA: 
1) Patients with ascites of other causes 
2) Patients who had received antibiotics 2 -3 weeks prior  
3) Patients with previous SBP 
4) Patients with secondary bacterial peritonitis 
5) Patients with infections involving other systems 
CLINICAL EVALUATION: 
A detailed history was obtained from the study group. Meticulous 
examination of the patient was done. Ascites was graded according to 
International Ascites Club criteria. West Haven criteria was used to grade the 
severity of Hepatic encephalopathy. The study group was subjected to 
Biochemical, Radiological investigations and Endoscopy. 
LABORATORY INVESTIGATIONS: 
Blood investigations - hemoglobin, WBC count, platelet count, serum 
bilirubin – total, direct, indirect, SGOT, SGPT, SAP, serum proteins – total, 
albumin, globulin, PT, INR, serum urea, serum creatinine, HBsAg, Anti HCV 
were done for all the patients. 
CTP class and MELD score was calculated for all the patients. 
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ASCITIC FLUID COLLECTION: 
Under strict aseptic precautions diagnostic paracentesis of the ascitic 
fluid was done. Proper  positioning of the patient was done. The site of tapping 
on the abdomen was marked by clinical or with ultrasound guidance.  Povidone 
iodine solution was used for skin disinfection. Abdominal draping was done 
with sterile towel. Sterile gloves were worn before performing the procedure. 
22 gauge needle was used for tapping . Z technique was applied for tapping of 
the fluid. 30 ml of the ascitic fluid was obtained using two syringes. The blood 
culture bottles were inoculated first. For ascitic fluid culture, about 10 ml of the 
ascitic fluid was inoculated directly into 50 ml blood culture bottles -aerobic 
and anerobic media each at the bedside itself under strict aseptic precautions 
and using a sterile needle.  
Ascitic fluid was also sent for analysis of total leucocyte count, 
polymorphonuclear neutrophil counts, total proteins, albumin, globulin, sugar, 
cytology, culture and sensitivity. 
Other relevant investigations like chest X- ray, ECG, plain X- ray 
abdomen, UGI endoscopy were also done . 
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DISTRIBUTION OF PATIENTS WITH CIRRHOSIS AND ASCITES 
AND THE STUDY GROUP: 
TOTAL OF 180 PATIENTS ADMITTED WITH ASCITES 
↓ 
80 patients were excluded 
23 patients had previous episodes of SBP, 22 patients had other causes 
of ascites like TB, Malignancy, 20 patients had co existent other system 
infections like UTI, Respiratory infections, cellulitis of foot etc, 15 
patients had prior antibiotic treatment. 
↓ 
100 patients included in the study 
 
 
29 pateints  -  SBP                 71patients –Non - SBP 
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RESULTS 
The total study group included 100 patients with cirrhosis and ascites. 
Of these 100 patients, 75(75%) patients were males and 25 (25%) were females 
with a male to female ratio of 3:1.Male preponderance was seen in this study 
group as the main etiology of the cirrhosis is ethanol related. SBP was found in 
28 male and 1 female patient and No SBP in 47 male and 24 female patients. 
TABLE – 1 : GENDER DISTRIBUTION OF THE STUDY GROUP 
(N=100 ) 
Among the study group of 100 cases, 75(75%) were male and 25(25%) 
were female with a male- female ratio of 3:1. 
GENDER SBP n=29(%) NONSBP n=71(%) TOTAL 
MALE 28(96.6) 47(66.2) 75(75) 
FEMALE 1(3.4) 24(33.8) 25(25) 
TOTAL 29(100) 71(100) 100(100) 
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AGE DISTRIBUTION: 
The mean age of the patients in SBP group is 44.24 ± 8.0 years and the 
mean age of the patients in Non– SBP group is 43.35 ± 6.0.There was only 
little difference in the mean age between the two groups and the P value was 
0.54 which was not statistically significant. 
TABLE 2: MEAN AGE OF THE SBP AND NON – SBP GROUPS: 
Variable SBP NON SBP P Value 
Age 44.24+8.00 43.35+6.00 0.54 
**Mean+ SD has been calculated for the variable 
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ETIOLOGY: 
The etiology of the study group is varied. In the SBP group the etiology 
was ethanol in 23(79.3%) patients, Hepatitis B in 6(20.7%) patients. In the Non 
– SBP group, the etiology was ethanol in 36(50.7%) patients, Hepatitis B in 
20(28.2%), Hepatitis C in 4(5.6%), NAFLD in 7(9.9%), Idiopathic in 4(5.6%) 
patients. Ethanol related cirrhosis was the commonest in both the groups but 
patients with ethanol related cirrhosis were found to be more prone to SBP (P< 
0.05)  
TABLE 3: ETIOLOGY IN SBP AND NON SBP GROUP 
ETIOLOGY 
GRADE 
SBP (n=29) NON SBP(n=71) Total 
n % n % n % 
1(Ethanol) 23 79.3 36 50.7 59 59 
2(HBV) 6 20.7 20 28.2 26 26 
3(HCV) 0 0 4 5.6 4 4 
4(NAFLD) 0 0 7 9.9 7 7 
5(IDIOPATHIC) 0 0 4 5.6 4 4 
TOTAL 29 100 71 100 100 100 
 
Variable SBP NON SBP P Value 
++Etiology 1(1-2) 1(1-5) 0.003* 
++Median (range) has been calculated for the variable. 
The Median of SBP and Non SBP groups is 1(Ethanol) group with range 
between 1-2 for SBP and 1-5 for NON SBP and there is highly significant 
difference in 2 groups (p< 0.01). 
*p< 0.05 is considered statistically significant. 
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CLINICAL SYMPTOMS:  
The patients presented with various clinical manifestations like ascites, 
pedal edema, fever, abdominal pain, jaundice, and UGI bleed. The patients also 
presented with various degrees of hepatic encepahalopathy at the time of 
hospitalization. Ascites was seen in all the patients of the study group. From 
the results it was seen that patients with SBP were found to be more commonly 
associated with fever, abdominal pain, jaundice, UGI bleed and with severe 
grades of Hepatic encephalopathy when compared to patients without SBP. 
COMPARISON OF CLINICAL SYMPTOMS BETWEEN  SBP AND 
NON SBP GROUPS 
Chi-square test and Fisher’s exact test have been used to compare the 
categorical variables wherever appropriate and p<0.05 is considered to be 
statistically significant. 
TABLE 4: DISTRIBUTION OF VARIOUS CLINICAL SYMPTOMS IN 
SBP AND NON SBP GROUPS 
Symptoms SBP n=29(%) 
NON SBP 
n=71(%) 
Total 
n=100(%) 
Abdominal Pain 24(82.8) 18(25.3) 42(42) 
Fever 17(58.6) 10(14.1) 27(27) 
Jaundice 16(55.2) 17(23.9) 33(33) 
UGI Bleeding 16(55.2) 11(15.5) 27(27) 
Pedal Edema 9(31) 21(29.6) 30(30) 
Abdominal distension 29(100) 71(100) 100(100) 
He 23(79.3) 17(23.9) 40(40) 
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TABLE 5 :  FEVER in SBP and NON SBP group 
FEVER 
GROUP 
Total 
P-ValueSBP NON SBP 
N % N % N % 
PRESENT 17 58.6 10 14.1 27 27 
<0.001* ABSENT 12 41.4 61 85.9 73 73 
Total 29 100 71 100 100 100 
OR - 8.64 ;   (95% C.I-      3.19-23.41) 
*p< 0.05 is considered statistically significant 
TABLE 6 :  ABDOMINAL PAIN IN SBP AND NON SBP GROUP 
ABDOMINAL 
PAIN 
Group 
TOTAL 
P-ValueSBP NON SBP 
N % N % N % 
PRESENT 24 82.8 18 25.3 42 42 
<0.001* ABSENT 5 17.2 53 74.7 58 58 
Total 29 100 71 100 100 100 
OR - 14.13 ;   (95% C.I-     4.70-42.54) 
*p< 0.05 is considered statistically significant 
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TABLE 7 : UGI BLEEDING IN  SBP AND NON SBP GROUP 
UGI 
BLEEDING 
GROUP 
Total 
P-ValueSBP NON SBP 
N % N % N % 
PRESENT 16 55.2 11 15.5 27 27 
<0.001*ABSENT 13 44.8 60 84.5 73 73 
TOTAL 29 100 71 100 100 100 
OR- 6.71 ;   (95% C.I- 2.54-17.78)  
*p< 0.05 is considered statistically significant 
TABLE 8 : HE SEVERITY IN SBP and NON- SBP 
SEVERITY 
GRADE 
SBP (n=29) NON SBP (n=71) Total 
n % n % N % 
1 6 20.7 54 76.1 60 60 
2 10 34.5 12 16.9 22 22 
3 13 44.8 5 7.0 18 18 
Total 29 100 71 100 100 100 
 
Variable SBP NON SBP P Value 
++ HE 
SEVERITY 
2(1-3) 1(1-3) <0.001* 
++Median (range) has been calculated(*p<0.05 is considered statistically 
significant).1 – west haven grade 0 &mhe,2 – west haven grade 1&2, 3- west 
haven grade 3 for statistical analysis 
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TABLE 9 : JAUNDICE IN SBP AND NON SBP GROUP 
JAUNDICE 
GROUP 
Total 
P-ValueSBP NON SBP 
N % N % N % 
PRESENT 16 55.2 17 23.9 33 33 
0.0026*ABSENT 13 44.8 54 76.1 67 67 
Total 29 100 71 100 100 100 
 
Odds Ratio-3.9(95% C.I-1.57-9.74).The odds of jaundice are 3.9 times greater 
among SBP group compared to non SBP group and it is found to be statistically 
significant.* p<0.05  is considered  statistically significant. 
TABLE 10 : PEDAL EDEMA IN  SBP AND NON SBP GROUP 
PEDAL 
EDEMA 
GROUP 
Total 
P-ValueSBP NON SBP 
N % N % N % 
PRESENT 9 31 21 29.6 30 30 
0.86 ABSENT 20 69 50 70.4 70 30 
Total 29 100 71 100 100 100 
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CHILD PUGH SCORE: 
Child Pugh Turcott score was calculated for all the patients. In the SBP 
group, majority of the patients were in Child Pugh class C(62.1%) and in Non – 
SBP group majority were in Child Pugh class B(59.2%).The occurrence of SBP 
was found to be statistically highly significant in patients with Child Pugh C (P 
< 0.01). 
TABLE 11 : CTP IN SBP AND NON SBP GROUP 
CTP Class 
SBP (n=29) NON SBP(n=71) Total 
N % n % N % 
A 0 0 6 8.5 6 6 
B 11 37.9 42 59.2 53 53 
C 18 62.1 23 32.3 41 41 
Total 29 100 71 100 100 100 
 
Variable SBP NON SBP P Value 
++CTP C(B-C) B(A-B) 0.0036* 
 
++Median (range) has been calculated for the variable . 
The median of SBP group is Class C compared to Class B for Non SBP 
group and there is a significant difference in 2 groups and it is found to be 
statistically highly significant (p<0.01) 
*p<0.05 is considered statistically significant. 
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MELD SCORE: 
MELD score was calculated for the study group. About 62.1% of 
patients with SBP had a MELD score ranging from 15 – 21 with a mean of 19. 
This score was found to be statistically significant (P < 0.001) in SBP patients. 
The MELD score was found to be in the range of 10 – 14 with a mean of 13 in 
the Non – SBP patients. 
TABLE 12 : MELD SCORE IN SBP AND NON SBP GROUPS 
MELD SCORE SBP n=29(%) NON SBP n=71(%) 
TOTAL 
n=100(%) 
1 (<=15) 8(27.6) 58(81.7) 66(66) 
2(16-24) 18(62.1) 12(16.9) 30(30) 
3(>=25) 3(10.3) 1(1.4) 4(4) 
Total 29(100) 71(100) 100(100) 
 
 
++MELD 
SCORE 
SBP NON SBP P VALUE 
2(1-3) 1(1-3)           <*0.001 
 
++Median (range) has been calculated for the variable. * p< 0.05 is considered  
statistically significant. The Median for SBP group lies in the 16-24 score 
group compared to the score of Non SBP group lying in <=15 group and there 
is a highly significant difference in the 2 groups with p<0.001. 
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ASSESSMENT OF BIOCHEMICAL PARAMETERS: 
Biochemical parameters were assessed among the two groups. Both 
serum and ascitic fluid were analyzed for various biochemical parameters 
including Hb, serum bilirubin, serum protein, serum albumin, serum creatinine, 
SGOT, SGPT, Platelet count, INR, Ascitic fluid total leucocyte count and 
polymorphonuclear neutrophil count, protein, albumin, cytology in the SBP 
and Non – SBP groups. Among these parameters ,the patients with SBP had 
statistically significant association than Non – SBP patients with regards to 
high ascitic fluid TLC (median of 620 vs. 170, P<0.001)high ascitic fluid PMN 
count (median of 420 vs. 82, P<0.001), low ascitic fluid albumin(mean of 
0.63±0.34 vs. 0.94±0.30, P<0.001), a low ascitic fluid protein(mean of 
1.15±0.34 vs. 2.27±0.64, P<0.001) a high serum bilirubin (mean of 6.81±6.12 
vs. 3.12±2.89, P<0.0001), a high SGOT (median of 58 vs. 40, P<0.05), a low 
Hb value (mean of 8.74±1.92 vs. 10.07±2.26, P<0.05) and a high INR value 
(mean of 1.67±0.52 vs.1.36±0.38, P<0.05). Others parameters were not 
statistically significant. This may indicate that patients with SBP are mostly 
anaemic with severe liver involvement and associated coagulopathy and mostly 
diseased due to ethanol with a low local and systemic immunity predisposing 
them to infections.   
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TABLE 13 : BIO CHEMICAL DATA IN SBP AND NON SBP GROUP 
Variable SBP NON SBP P Value 
**Serum Bilirubin 6.81+6.12 3.12+2.89 <0.001* 
 
**Serum Protein 6.34+0.98 6.65+0.81 0.10 
 
**Serum Creatinine 0.88+0.21 0.81+0.17 0.09 
 
**A.Albumin 0.63+0.34 0.94+0.30 <0.001* 
 
++Plt ct 165000(32000-
251000) 
160000(72000-
298000) 
0.39 
 
++SGOT 58(19-199) 40(12-199) 0.027* 
 
++SGPT 34(12-110) 32(12-138) 0.87 
 
**Hb 8.74+1.92 10.07+2.26 0.0063* 
 
++A.TLC 620(400-
48000) 
170(100-300) <0.001* 
 
**S.Albumin 3.12+0.78 3.12+0.56 0.98 
 
**INR 1.67+0.52 1.36+0.38 0.0013* 
++MELD 19(9-27) 13(6-31) <0.001* 
++A PMN 420(252-
33120) 
82(15-189) <0.001* 
A.PROTEIN 1.15+0.34 2.27+0.64 <0.001 
**Mean+ SD has been calculated for the variables. 
++Median (range) has been calculated for the variables. 
T test and Mann Whitney U test have been used to compare the variables 
between 2 groups accordingly and * p< 0.05 is considered statistically 
significant. 
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PREVALENCE OF SBP AND MICROBIAL CULTURE: 
The reports revealed the following. 29 patients were found to have SBP, 
among which 7 were classic SBP and the remaining 22 were culture negative 
(i.e. CNNA) and 71 were Non – SBP patients. There was no case of 
bacterascites. The results of the bacterial culture in the 7 patients revealed 
Escherichia coli in 4 patients and Klebsiella pneumonia in 3 patients.  
TABLE 14: PREVALENCE OF SBP: 
TOTAL 
CLASSIC SBP 
(culture positive, 
PMN≥250) 
CNNA (culture 
negative, 
PMN≥250) 
NON –SBP (culture 
negative, PMN>250) 
100 7 22 71 
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OUTCOME :  
The outcome of the patients with SBP and Non – SBP patients were 
analyzed. They were followed up for a period of 3 weeks. 5 patients in the SBP 
group, 4 patients with Classic SBP and 1 patient with CNNA died due to 
various reasons. In the Non – SBP group 3 patients died .The remaining 
patients in both the groups improved with appropriate antibiotic and other 
standard of care treatment. The patients with SBP as compared to Non – SBP 
patients have a higher mortality and the patients with Classic SBP (culture 
positive) have more mortality than CNNA (culture negative) patients (80% vs. 
20%). 
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TABLE 15 : MORTALITY in SBP and NON SBP group 
GROUP 
MORTALITY 
Total 
P-ValueYES NO 
N % N % N % 
 SBP 5 62.5 24 26.1 29 29 
0.043* NON SBP 3 37.5 68 73.9 71 71 
Total 8 100 92 100 100 100 
  
(Odds Ratio - 4.72 ; 95% C.I-1.05 - 21.27)  The odds of mortality are 
4.72 times greater among SBP group compared to non SBP group and it is 
found to be statistically significant. (p<0.05) 
* p< 0.05  is considered  statistically significant 
TABLE 16: PERCENTAGE OF MORTALITY IN CLASSIC SBP AND 
CNNA PATIENTS 
CLASSIC SBP(culture 
positive) 
CNNA (culture 
negative) 
TOTAL 
4(80%) 1(20%) 5(100%) 
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DISCUSSION 
The prevalence of SBP in patients admitted with cirrhosis, ascites and 
with symptoms & signs suspicious of SBP is found to be 29% in our study. It is 
almost similar to the study done by Amarapurkar DN et al(81) from India with a 
prevalence of 22%. Similar study by Andreu et al(43) reported a prevalence of 
SBP of 28%. Various studies have reported a prevalence of 10-30%,which is 
well comparable with this study. The diagnosis of SBP in this study was based 
on the criteria proposed by Hoefs and Runyon(9): patients with clinical signs & 
symptoms of peritonitis, a positive ascitic fluid culture and ascitic fluid PMN 
count > 250 cells/cumm. The prevalence of SBP in this study is found to be 
similar to other studies. 
The mean age of diagnosis of SBP in many of the Indian studies have 
been reported to be ranging from 39-44 yrs(82). In this study the mean age was 
around 44 yrs which is comparable with other studies. 
The predominant etiology in patients with SBP in this study was found 
to be due to ethanol related cirrhosis (79.3% in SBP and 50.7% in Non – SBP 
group), as during this period of study the majority of patients were due to 
ethanol related cirrhosis and the majority were males who frequently consume 
significant amounts of alcohol and present more frequently with advanced liver 
disease. This was in concordance with other studies. Lata et al(83) in their study 
have reported that the prevalence of SBP is higher in the patients with cirrhosis 
caused by alcohol consumption rather than by viral hepatitis . 
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This study showed similarity in the clinical presentations of the patients 
with SBP with other studies. Ascites was seen in all patients, Abdominal pain 
in 82%, Hepatic encephalopathy in 79 %, Fever in 58.6%, Jaundice and UGI 
bleed in 55%, and Pedal edema in 31%. Mihas et al(84) reported fever in 
54%,abdominal pain in 57% and Hepatic encephalopathy in 67%.In the study 
by Amarapurkar DN et al(81), abdominal  pain was the predominant symptom 
followed by fever and encephalopathy. The predominance of  jaundice in this 
study may be due to the more number of patients in advanced stage of the 
disease. SBP may also have a non- specific clinical picture and is usually 
manifested by deepening of symptoms that accompany the liver cirrhosis and 
does not always have the classical signs and symptoms of SBP. Occurrence of 
SBP in asymptomatic patients also have been described in various clinical 
studies. 
Jain et al(85) in their study reported a prevalence of SBP in 34.92%, out 
of 63 patients and all patients were in Child Pugh class C . Puri AS et al (86) 
also have reported a prevalence of SBP and its variants in 30% (21 out of 70) 
of the patients and 77% of the patients were in class C. In this study of 100 
patients, 29(29%) were found have SBP, 7(24.2%) were found to be culture 
positive and 22(75.8%) patients were found to be culture negative (CNNA) and 
62.1% of the patients with SBP were in Child class C ,which is consistent with 
other studies. The study by Amarapurkar DN et al(81) also revealed that the 
majority of the patients with SBP and its variants belonged to Child class C. 
The severity of the liver disease is the most important predisposing factor for 
the development of SBP.   
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One important finding from this study was a statistically significant 
association of a higher MELD score with SBP. The risk of SBP increases in 
patients with moderate to high MELD scores. This may indicate that MELD 
score can be used as a tool in predicting the development of SBP and its 
association with mortality. This study showed that a MELD score of 19 
(median 15 -21) was associated with an increased risk of SBP. Similar result 
was seen in a study by Gayatri et al(87) which revealed an increased risk of SBP 
with a MELD score of ≥18. Obstein et al(35) showed that the mean MELD score 
of patients with SBP was 24.A high MELD score may be seen in patients with 
advanced liver disease which is associated with an impaired immunological 
clearance and also an increase in the intestinal permeability and bacterial 
translocation and hence increased risk of ascitic fluid infections. 
The biochemical analysis of serum and ascitic fluid between the two 
groups of patients revealed that patients with SBP were found have a 
statistically significant association with a high ascitic fluid total leucocyte 
count with a mean of 620 cells. A low ascitic fluid albumin level was seen with 
a mean of  0.63 ± 0.34 gm/dl compared to 0.94 ± 0.30 in Non – SBP group, a 
low ascitic fluid protein level was seen with a mean of 1.15 ± 0.34 compared to 
2.27 ± 0.64 in Non –SBP group and a high ascitic fluid PMN with a mean of 
420 cells. Majority of the patients in the SBP group with culture positivity had 
ascitic fluid protein levels < 1 g/dl. In the Runyon BA series(88) those patients 
with a ascitic fluid protein <1 g/dl were found to be more predisposed to SBP. 
In the study by Amarapurkar DN et al(81) the mean ascitic fluid protein was 
0.78±0.24 gm/dl in patients with SBP. In this study the mean ascitic fluid 
protein is 1.1±0.34 which is almost similar to other studies. 
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The patients with SBP were found to have statistical significant 
association with a high levels of sr bilirubin, a high SGOT levels and a low Hb 
levels. This might may be due to its relation with the advanced stage of the 
liver disease. Guarner C et al(44) in their study have found that cirrhotic patients 
with low ascitic fluid protein, with high bilirubin levels and/or low platelet 
count are at higher risk of acquiring first episode of community – acquired 
SBP. In this study there was no significant difference in the platelet count 
between the two groups. There was also no difference between the two groups 
in sr protein, sr creatinine, SGPT, sr albumin levels  as the patients in both the 
group were equally deficient in their liver functioning. 
The INR was found to be significantly higher in the SBP patients as 
compared to the Non-SBP (1.67 ± 0.52 vs.1.36 ± 0.38, P<0.05) indicating 
advanced stage of the liver disease. 
In this study the most frequent organism isolated was E coli (4 cases, 
57.10%) followed by Klebsiella (3cases, 42.90%). The results were similar to 
other studies by Runyon et al and Wilcox et al(23) which showed that 27.3% and 
45% of cases of SBP were due to E coli respectively. This study result was also 
comparable to a similar study conducted in a tertiary care hospital at Karnataka 
which showed E coli in 62.5% and Klebsiella in 25% of cases(89).  
The mortality in this study was seen in 62.5% of SBP (4 cases in classic 
SBP - 80% and 1 case in CNNA – 20%) and 37.5% of Non- SBP patients. SBP 
patients are found to be significantly associated with mortality (P-0.043). 
Runyon and Hoefs(11) in their study reported a mortality of 70% and 50% 
respectively in culture positive and negative patients. An another study by 
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Pelletier et al(90) also revealed a higher mortality with culture positive SBP 
patients as compared to patients with CNNA. Lower mortality rate with CNNA 
may indicate that it is a less severe variant of SBP and patients might have a 
better liver function as compared to patients with Classic SBP. The patients 
were started on empirical antibiotic treatment of Inj Cefotaxim 2 g IV tds, with 
also other  standard treatment of care to prevent HRS and worsening of the 
disease. These patients were kept under close monitoring and follow up. The 
SBP patients were followed up until their discharge until 3 weeks. Out of the 5 
patients who died, 2 patients developed HRS inspite of antibiotic treatment and 
albumin infusion, out of which one patient died on the 5th day and one patient 
died on the 7th day not responding to treatment. One patient had a massive 
bout of UGI bleed on the third day and succumbed to death. Two patients died 
due to hepatic encephalopathy. 
The mortality in SBP patients in spite of antibiotic treatment might be 
probably due to their poor response to antibiotics, development of HRS and 
progression the underlying liver disease. 
The mortality in 2 of the Non- SBP patients were related to UGI bleed 
and 1patient died due to hepatic encephalopathy .The poor survival in SBP 
patients can be well explained by their advanced nature of liver disease, 
immunological impairment, development of drug resistance, poor response to 
drug therapy and renal impairment.  
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CONCLUSION 
1) SBP is seen in 29% of patients with cirrhosis and ascites  
2) Classic SBP is seen in one – third and CNNA in two – thirds of 
the patients with SBP. 
3) E coli is the commonest organism grown. Next is Klebsiella. 
4) SBP is common in alcoholic cirrhotics.   
5) Low ascitic fluid protein levels, high sr bilirubin, high INR, high 
MELD score and Child class C are risk factors for SBP. 
6) Abdominal pain, Fever are common in patients with SBP. 
7) SBP can be fatal in patients with cirrhosis and ascites. 
8) The mortality in patients with culture positive SBP (Classic SBP) 
is more frequent than with culture negative SBP (CNNA).   
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PROFORMA 
 
Name:            Age:           Sex:         Address:       MGE No: 
Clinical history: 
Abdominal pain                                                    Fever  
Abdominal tenderness                                           Jaundice 
Recent increase in abdominal distension               UGI bleed 
Past history: 
Diabetes mellitus                               Hyperlipidemia 
Hypertension                                     Renal problems  
Previous episodes of SBP  
Drug history: 
Personal history: 
General examination: 
 
Pallor, icterus, pedal edema, cyanosis, clubbing, 
lymphadenopathy,  
signs of liver cell failure. 
Vitals:    PR:     HR:     Temp:     BP: 
JVP: 
System examination:  
ABD:      CVS:        RS:         CNS: 
Investigations: 
CBC :                    Platelet Ct :                   RFT : 
LFT :                       PT :                            INR :  
HBsAg :                 Anti HCV :                    HIV : 
Blood Sugar: 
Ascitic fluid analysis : 
Total count           Differential Ct              Total proteins 
Albumin               Globulin                       Sugar 
Cytology                Culture &Sensitivity 
USG Abd: 
Chest X- ray: 
Plain X- ray Abdomen: 
UGI Endoscopy : 
ECG: 
CTP score :                       MELD score: 
 
NAME age
MGE 
NO S bilirubin Salbumin Sprotein
Screatini
ne SGOT SGPT INR CTP class MELD Plt ct A albumin A protein
lakshmi 45/F 4214 0.6 3.3 6 0.5 31 20 0.91 B 6 115,000 0.4 1.4
poondian 39 /M 1348 0.9 3.5 6.8 0.8 12 15 1.15 B 8 122,000 1 1.6
kathiresan 42/M 4323 3.5 2.9 6.3 0.6 57 50 1.33 C 14 200,000 0.8 1.2
murugan 33/M 999 3.7 4.8 7.6 0.9 35 22 1.18 B 13 210,000 0.9 1.3
venkatesh 31/M 1283 1 3.6 6.6 0.6 45 32 1.28 B 9 168,000 0.7 1
varadhan 40/M 3842 0.7 3.7 7 0.9 34 28 1.09 B 7 130,000 0.4 1.1
parameswaran 35/M 1994 4.5 3 7.3 0.8 169 129 1.2 C 14 72,000 0.6 1.3
edward 41/M 6845 1.6 3.2 7 1 72 68 1.24 B 11 232,000 0.4 1.6
gnanaprakasam 39/M 2309 1.5 2.9 6.4 0.9 118 28 1.1 C 9 193,000 0.7 1.7
kanagammal 45/F 1562 2 2.5 6 0.5 26 22 1.63 C 15 220,000 0.8 1.9
barathi 39/F 2321 9.2 3.1 6.4 1.2 54 26 1.8 C 23 120,000 1.2 1.9
sekar 49/M 7511 1.3 2.9 5.8 0.8 40 32 1.26 B 10 246,000 1.8 2.4
nehru 50/M 7826 10.5 2.4 6.8 0.9 67 60 1.01 C 15 85,000 1.3 2
govindaraj 36/M 7142 8.8 3.7 8.8 0.6 67 79 1.21 B 17 128,000 2 3.5
karunagaran 38/M 1468 1 2.7 6.8 0.6 30 20 1.18 B 8 228,000 1.2 2.2
chinnasamy 43/M 916 3.9 2.7 6.9 0.6 20 24 1.21 C 14 171,000 0.7 1.8
dasaradhann 37/M 7463 7.8 2.8 6 0.7 70 65 1.12 C 15 212,000 0.9 2.2
kadar 38/M 8120 4.5 3 5.8 0.9 26 34 1.14 B 14 150,000 1.5 3
kasthuri 44/F 6526 3 2.9 6.5 0.8 91 79 1.2 B 13 138,000 1.2 1.9
deivanai 39/F 4544 2.2 3 6 1 150 96 1.5 B 14 112,000 0.8 2.5
parimala 32/F 1150 4.3 2.5 5.8 0.5 130 59 1.4 C 16 96,000 1.1 2.4
kavitha 49/F 3554 5.2 2.5 6 0.6 27 21 1.06 C 13 160,000 1.2 1.8
kumaravel 37/M 2654 7.5 3 6.2 0.9 31 14 1.01 B 14 210,000 0.8 1.9
natchimuthu 49/M 4111 2 2.8 6 1.1 44 65 1.46 B 14 290,000 0.9 2
dasaradhann 51/M 3467 3.4 2.4 5.9 0.8 26 40 1.26 C 14 185,000 1 1.9
indirani 47/M 1213 2.5 2.5 5.5 0.9 16 14 1.09 B 11 242,000 1.3 2.5
maniammal 37/F 2661 10.8 2.5 5 1.2 38 34 1.43 C 21 98,000 1.1 1.9
loganayagi 40/F 4943 8.5 2.9 6 0.8 53 69 1.53 C 19 210,000 1.2 2
amaravathy 50/F 3095 6 3.1 6.2 0.9 40 64 1.72 C 19 125,000 0.8 1.8
meerjama hussain 51/M 851 1.3 2.4 6 1.1 40 18 1.26 B 14 110,000 1.2 3
ambiga 35/F 6474 1.5 2.8 6.2 0.8 91 79 1.72 B 14 112,000 0.6 1.5
mahalaxmi 39/F 1177 3.6 2.7 5.8 0.9 42 18 1.12 C 13 213,000 0.9 2.4
hemavathy 43/F 3283 2.6 3.4 7.8 0.6 48 62 1.47 C 14 190,000 1 3.2
sivakumar 45/M 688 7.7 2.9 6.5 0.8 40 28 0.98 B 14 200,000 1.1 1.9
sundar 47/M 730 2 2.5 5 0.9 24 19 1.15 B 11 168,000 0.9 2.6
mohan 42/M 605 5.5 3 6 0.7 28 38 1.9 C 20 150,000 0.8 1.8
sridar 38/M 591 3.5 2.9 5.8 0.9 47 57 1.7 C 17 100,000 0.9 1.5
kabaleeswaran 37/M 557 1.3 2.5 5.5 0.8 32 38 1.26 B 10 96,000 0.6 1.8
nagaraj 46/M 517 3.8 2.7 6.5 1 14 20 1.14 C 13 152,000 0.7 2.5
raja 36/M 515 2.5 3.2 7 0.9 20 30 1.19 B 12 182,000 0.9 2.8
chandran 45/M 560 3.5 2.6 6.2 1.1 92 49 1.81 C 19 175,000 1 3.2
suseela 47/F 12245 1.1 2.3 6.4 0.6 53 17 1.72 B 13 211,000 0.8 2.5
mohana 49/F 1654 0.7 3.6 6 0.8 27 14 1.2 B 8 180,000 0.6 2.8
radha 45/F 165 1.5 3.4 7.9 0.6 40 21 1.48 B 12 240,000 0.9 1.8
santhanam 53/M 2935 3.5 3.1 6.8 0.9 23 21 1.23 C 13 120,000 0.7 2.2
karunakaran 51/M 2632 1 3.7 6.5 1.1 38 34 1.36 A 11 210,000 0.8 3.2
parveen 46/F 267 0.6 3.2 7 0.8 16 19 1.2 B 8 250,000 1 3
chandrasekar 44/M 3271 1.8 3.3 7.5 0.9 12 15 1.9 B 16 180,000 0.9 1.9
paneerselvam 38/M 3579 1.2 2.5 6.4 0.8 54 30 1.7 B 13 160,000 0.8 2.5
padma 55/F 1547 0.8 3.3 6.8 0.6 60 37 1.06 B 7 110,000 0.5 2.8
purushothaman 45/M 2104 2.9 3.4 7.7 0.6 32 44 1.2 B 12 175,000 0.9 1.9
stella 33/F 2094 1.5 4.9 7.5 0.6 17 14 1.39 A 12 128,000 1.2 2.4
neelakandan 49/M 1990 14.9 2.5 7.6 0.8 23 18 3.67 C 31 115,000 1.3 2.8
krishnamoorthy 43/M 2135 1.3 3 8.1 0.8 64 42 1.47 B 12 100,000 0.6 2
rajalingam 48/M 7079 1.2 3.4 5.3 0.7 24 34 1.2 B 9 128,000 1.2 3.6
dass 46/M 432 1 2.9 7.2 0.8 14 12 1.39 B 10 250,000 1.6 2.8
ilangovan 39/M 920 3.8 3 7 0.9 19 24 1.9 C 19 275,000 0.8 2
vijayakumar 53/M 6286 1.9 4.2 7.1 0.8 35 46 2.01 B 17 100,000 1.2 3.6
simson 54/M 34479 1.7 3.5 7 0.9 70 109 1.27 B 11 190,000 1.1 3
kumar 45/M 7997 3.3 3.9 7.2 0.6 199 104 1.06 B 12 145,000 0.7 1.5
ayyanar 43/M 6556 1.6 3 6.8 0.9 20 28 1.16 B 10 298,000 1.2 2.8
mariappan 42/M 6549 0.9 3.5 7.5 0.8 30 25 1.27 B 9 192,000 0.8 2
ramanathan 45/M 4038 0.7 2.9 6.4 1.2 106 79 1.2 B 10 80,000 0.8 1.9
tamilselvan 37/M 4167 0.5 3 7.8 0.9 131 44 1.2 B 8 115,000 0.6 2.2
sampath 49/M 5498 1.5 3.3 7.4 0.9 49 57 1.19 B 10 96,000 0.5 2.6
sengalvarayan 55/M 6137 1.6 3.6 7.6 0.7 128 138 1.39 A 12 210,000 0.9 3
paneerselvam 43/M 2878 0.6 4.6 9 1 54 30 1.06 A 7 160,000 0.8 1.9
saraswathy 47/F 4421 0.5 4.4 6.7 0.7 20 24 1.19 A 8 138,000 1.1 3
usharani 35/F 3271 1.6 3.2 6 0.9 37 40 1.38 B 12 168,000 0.8 2.9
partheeban 47/M 4532 1.5 3.8 6.7 0.8 42 70 1.46 A 12 150,000 1.1 3.5
sundar 53/M 4631 4 3 7.6 0.6 84 32 1.26 B 14 112,000 1.2 3.2
A TLC APMN Hb etiology culture outcome
SYMPTO
MS
200 30 5.6 HBV negative improved abd distn A A no jaundice A pedal edema no he
300 90 13.8 ethanol negative death abd distn A A no jaundice ugi bleed A no he
100 20 9.8 ETHANOL negative improved abd distn A fever no jaundice A A he 2
150 15 10.6 ETHANOL negative improved abd distn abd pain A jaundice A no he
200 40 9.9 ETHANOL negative improved abd distn A A no jaundice A pedal edema he 2
100 22 11.2 HBV negative improved abd distn Absent A no jaundice A A no he
170 17 10.2 ETHANOL negative improved abd distn abd pain A jaundice A A no he
110 15 6.2 ETHANOL negative improved abd distn abd pain A no jaundice A A he 3
100 25 7.3 ETHANOL negative improved abd distn A fever no jaundice A A no he
100 45 11.2 HBV negative improved abd distn A A no jaundice A pedal edema he 2
100 56 6.8 hcv negative improved abd distn A A jaundice A pedal edema no he
300 60 8.8 ethanol negative improved abd distn A A no jaundice ugi bleed A no he
200 64 9 ethanol negative improved abd distn abd pain A jaundice A pedal edema he 2
100 52 8.3 ethanol negative death abd distn A A jaundice A pedal edema he 3
200 80 14.6 hcv negative improved abd distn A A no jaundice A pedal edema he 2
100 48 11.6 hbv negative improved abd distn abd pain A no jaundice A pedal edema no he
100 66 9.2 ethanol negative improved abd distn A fever jaundice A A he 2
200 50 10 ethanol negative improved abd distn abd pain A jaundice A pedal edema no he
150 45 10.2 nafld negative improved abd distn A A no jaundice ugi bleed A no he
270 189 9.8 hbv negative improved abd distn A A no jaundice A A no he
200 88 7.6 idiopathic negative improved abd distn abd pain A jaundice A A no he
300 171 6.4 nafld negative improved abd distn A A jaundice A A no he
170 68 9.8 ethanol negative improved abd distn A A jaundice ugi bleed A no he
200 162 11.2 ethanol negative improved abd distn abd pain A no jaundice A A he 2
300 132 12.8 ETHANOL negative improved abd distn A A no jaundice A A no he
200 108 11.5 nafld negative improved abd distn A A no jaundice A A no he
200 180 9.44 hbv negative improved abd distn A A jaundice ugi bleed A he 2
100 59 12.6 HBV negative improved abd distn A A jaundice A A no he
300 159 6.8 nafld negative improved abd distn abd pain A jaundice A A no he
100 78 7.8 NAFLD negative improved abd distn A fever no jaundice A A no he
100 84 8.5 hbv negative improved abd distn A A no jaundice A A no he
200 138 11.4 HBV negative improved abd distn abd pain A no jaundice A A no he
200 144 7.1 ethanol negative improved abd distn A A no jaundice A A no he
300 162 13 ETHANOL negative improved abd distn A fever jaundice A A no he
100 75 12.6 ETHANOL negative improved abd distn abd pain A no jaundice A A no he
200 96 11 ETHANOL negative improved abd distn A A jaundice ugi bleed A he 2
300 171 11 HBV negative improved abd distn A A no jaundice A pedal edema he2
200 134 6.3 ETHANOL negative improved abd distn abd pain A no jaundice A A no he
100 88 6.4 ETHANOL negative improved abd distn A A no jaundice A A no he
100 92 7.6 ETHANOL negative improved abd distn abd pain A no jaundice A A no he
200 116 13 HBV negative improved abd distn A A no jaundice A pedal edema he 2
100 63 11 hbv negative improved abd distn A fever no jaundice A A no he
100 48 6.6 HBV negative improved abd distn abd pain A no jaundice A A no he
100 58 12.2 idiopathic negative improved abd distn A A no jaundice A A no he
100 81 10.8 HBV negative improved abd distn A A no jaundice ugi bleed pedal edema no he
200 126 7.6 ETHANOL negative death abd distn A A no jaundice A pedal edema no he
100 94 13 idiopathic negative improved abd distn abd pain A no jaundice A A no he
100 82 7.5 ETHANOL negative improved abd distn A A no jaundice ugi bleed pedal edema no he
100 73 10.8 ETHANOL negative improved abd distn A fever no jaundice A A no he
100 69 8 nafld negative improved abd distn A A no jaundice A A no he
200 142 7.5 ethanol negative improved abd distn abd pain A no jaundice A pedal edema no he
200 112 9.8 HBV negative improved abd distn A A no jaundice A A no he
200 98 13 ETHANOL negative improved abd distn A A jaundice A pedal edema  he 3
100 64 12.6 ETHANOL negative improved abd distn A fever no jaundice A A no he
100 58 10.6 ETHANOL negative improved abd distn A A no jaundice A A no he
200 136 11.7 ETHANOL negative improved abd distn A A no jaundice ugi bleed A no he
200 110 11 ETHANOL negative improved abd distn A A no jaundice A A he 3
200 114 10 HBV negative improved abd distn A A no jaundice A pedal edema no he
200 96 7.4 ETHANOL negative improved abd distn A A no jaundice ugi bleed A no he
200 124 10 ETHANOL negative improved abd distn A A no jaundice A A no he
100 65 13 HBV negative improved abd distn abd pain A no jaundice A A no he
200 102 11.8 ETHANOL negative improved abd distn A fever no jaundice A A no he
100 78 14 HCV negative improved abd distn A A no jaundice A pedal edema he 3
200 94 7 ETHANOL negative improved abd distn A A no jaundice ugi bleed A he 2
100 85 11 HBV negative improved abd distn A A no jaundice A pedal edema no he
100 56 13 NAFLD negative improved abd distn abd pain A no jaundice A A no he
200 184 10.8 hcv negative improved abd distn A A no jaundice A A no he
100 38 10.9 hbv negative improved abd distn A A no jaundice A pedal edema no he
100 44 10.6 IDIOPATHIC negative improved abd distn abd pain A no jaundice A A no he
100 86 13 HBV negative improved abd distn A fever no jaundice A A no he
200 106 11.4 ethanol negative improved abd distn A A jaundice A pedal edema no he
